The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical trial of the intraperitoneal (IP) administration of a novel nanoparticle formulation of paclitaxel (NTX).
Stephen K. Williamson
Research Funding - CritiTech
Jo Wick
No relevant relationships to disclose
Julia A. Chapman
No relevant relationships to disclose
Gary Johnson
No relevant relationships to disclose
Greg Reed
No relevant relationships to disclose
Thomas K. Schulz
No relevant relationships to disclose
Holly Smith
No relevant relationships to disclose
Scott Weir
No relevant relationships to disclose
Charles J Decedue
Employment or Leadership Position - CritiTech
Stock Ownership - CritiTech
Jahna Howell
Employment or Leadership Position - CritiTech
Stock Ownership - CritiTech
Katherine Roby
No relevant relationships to disclose